Read More


Showing 211–225 of 225
Practice areas
Show all
Counsel Financial Adds Talc Cases to Enter Mass Torts® Program
Robert Carbone, Esq. | Deputy General Counsel, Attorney Relations
Program Offers Business Development Opportunity for Non-Mass Tort Lawyers. Addition of Talc Comes After $72 Million Verdict Against J&J in February 2016.
Counsel Financial Honored by Five-Year Exclusive Endorsement from The National Trial Lawyers
Kim Gomlak | Marketing Director
Trial Lawyers’ Association Recommends Lender to Plaintiffs’ Counsel Nationwide
Taxotere is an intravenous chemotherapy drug developed and manufactured by Sanofi.[1] The FDA approved the drug in 1996 for the treatment of breast cancer, non-small cell lung cancer, advanced stomach cancer, head and neck cancer and prostate cancer.[2]
Counsel Financial Ramps Up Lending Operations for Louisiana Plaintiffs' Attorneys
Kim Gomlak | Marketing Director
Lender Focusing on Louisiana as Key State | Announces New Facilities with Growing Louisiana Firms
Viagra (sildenafil citrate) was introduced by Pfizer in 1998, and it has become one of the most widely recognized brand-name medications on the market in the United States—used by millions of men to treat impotence and sexual erectile dysfunction (“ED”).
PwC Back in Crosshairs of Madoff Feeder Fund Class Action
Robert Carbone, Esq. | Deputy General Counsel, Attorney Relations PricewaterhouseCoopers LLP (“PwC”), an international accounting firm, and The Citco Group Ltd. (“Citco”), a financial services group, are back at the center of a class action led by investors in several feeder funds that invested in the historic Ponzi scheme architected by Bernie Madoff. The action pleads federal securities law and state law violations arising out of PwC’s role as auditor of the funds and Citco’s part as the funds’ administrator and custodian.  On March 3, 2015, a ju
$5.7 Million Verdict Awarded in Ethicon Transvaginal Mesh Trial
Kelly Anthony, Esq. | Deputy General Counsel
A jury in Bakersfield, California, has returned a $5.7 million verdict against Johnson & Johnson and its subsidiary, Ethicon Inc., after finding that Ethicon’s TVT Abbrevo transvaginal mesh device was defectively designed and that Ethicon failed to warn doctors of the risks associated with the product. The lead plaintiff in the case, Coleen Perry, a retired caterer, was implanted with the TVT Abbrevo system in 2011 to treat stress urinary incontinence. Within one year of implantation, Mrs.
Plaintiffs around the country have filed claims for injuries sustained after taking the anti-nausea medication, Zofran, originally manufactured by GlaxoSmithKline, LLC (“GSK”).[1] Plaintiffs in the Zofran litigation claim that prenatal exposure to the drug caused their children to be born with severe birth defects and that the defendant drug manufacturers (1) “unlawfully promoted Zofran for ‘off-label’ use during pregnancy; (2) hid evidence that Zofran can increase the risk for congenital defects; and (3) failed to warn the public of Zofran’s alleged risks.”[2]
Syngenta is a multibillion-dollar global agribusiness enterprise that develops and produces genetically modified corn seed. In 2010, the U.S. Department of Agriculture determined that a corn line developed by Syngenta, known as Agrisure Viptera (designated as transformation event MIR162—a seed designed to be insect-resistant), was no longer considered “regulated” under the regulations governing the introduction of certain genetically engineered organisms (the GMO Regulations and the Plant Protection Act).
In February 2014, the first case involving AndroGel, a testosterone replacement therapy, was filed against AbbVie Inc., Abbott Laboratories and Eli Lilly and Company (“Defendants”) in the United States District Court for the Northern District of Illinois. One month later, Hon. Matthew F. Kennelly ordered that over 30 lawsuits be consolidated in the same court for coordinated or consolidated pretrial proceedings.
Propecia is a well-known oral prescription medication used for the treatment of hair loss in men, also known as androgenetic alopecia. Androgenetic alopecia is a genetic disorder that effects 70% of men at some point in their lifetime and approximately 35 million men in the United States. The active ingredient in Propecia is finasteride, a synthetic four-azasteriod compound. Finasteride lowers the level of androgens in men, such as testosterone. Essentially, finasteride prevents the conversion of testosterone to dihydrotesterone in the body, which has been implicated in the balding process.
Risperdal is the brand name for risperidone, an atypical or “second generation” antipsychotic drug prescribed to treat schizophrenia and other manifestations of psychotic disorders. Defendants named in the consolidated litigation are the designers, developers, manufacturers, marketers, advertisers, distributors and/or sellers of the drug, including Johnson & Johnson (“J&J”) and its subsidiary, Janssen Pharmaceutica (“Janssen,” and together, “Defendants”).
Fresenius’ website, “GranuFlo is the most-widely prescribed dry acid product in the dialysis industry today.”
The ASR hip implants are metal-on-metal devices made of chromium and cobalt. The devices include a cup that is implanted into the hip with a ball joint that connects to the leg. The ASR metal-on-metal implants reconstruct human hip joints that were diseased due to conditions such as osteoarthritis, rheumatoid arthritis, avascular necrosis or fracture. Once implanted, the devices are supposed to last for an average of 15 years. 
Over 1,200 lawsuits involving claims that talcum powder causes ovarian cancer have been filed – mostly in St. Louis and New Jersey. Plaintiffs in the lawsuits involving cosmetic talc-based products allege that long-term use can cause the development of ovarian cancer. Defendants named in the litigation are: the manufacturer of the products, Johnson & Johnson; its parent company, Johnson & Johnson Consumer Companies; the company that mines the talc for the manufacturer, Imerys Talc America f/k/a Luzenac America; and the trade associate responsible for representing industry interest and lobbying on against regulation of talc.